Arius Research Inc. and Goodwin Biotechnology, Inc. Sign Antibody Manufacturing Agreement.Business Editors & Health/Medical Writers BIOWIRE2K PLANTATION, Fla.--(BW HealthWire)--July 25, 2001 Goodwin Biotechnology, Inc. (GBI GBI Georgia Bureau of Investigation GBI Green Building Initiative GBI Ground Based Interceptor GBI Grand Bahama Island GBI Green Bank Interferometer GBI Generic Bus Interface GBI Gain By Inventory GBI Garrett Bureau of Investigation ) announced today that Arius Research Inc. (CDNX CDNX See Canadian Venture Exchange (CDNX). :YAR YAR You Are Right YAR Yemen Arab Republic YAR Youth As Resources YAR York Antwerp Rules YAR Youth At Risk YAR Yet Another Repository (Perl) YAR Young Australians for a Republic YAR Yearly Accomplishment Report ) of Toronto, Canada, has contracted with GBI to manufacture supplies of ARIUS' antibodies, AR460-23 and AR5LAC-20 for their upcoming cancer studies in humans. "Strong interest in antibodies has put pressure on worldwide manufacturing capacity," said Dongxiu Qiu, head of scientific operations for ARIUS. "Goodwin has a strong track record in antibody manufacture in accordance with FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. requirements. Establishing this contract will provide us with the quality and supply we need to ensure next spring's Phase 1 studies are on track." Brandon J. Price, Ph.D., GBI's president, stated, "We are pleased to be working with one of the leading biotechnology companies in development of potentially important treatments for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , breast cancer, and melanoma - all diseases of serious consequence worldwide. Our aim is to assist ARIUS in bringing their monoclonal antibody compounds quickly and safely into human clinical trials." GBI is a fully integrated biologics contract manufacturer based in Plantation, Florida that specializes in cGMP-compliant manufacture of recombinant products for Phase I/II human clinical trials. GBI is especially well known for its expertise in monoclonal antibody production (for both the therapeutic and diagnostic industries). Being fully integrated, GBI can also handle cell-line engineering, cell banking (MCB (Memory Control Block) An identifier (16 bytes) that DOS places in front of each block of memory it allocates. and WCB WCB Workers Compensation Board (Canada) WCB Write Combining Buffer WCB Wheelchair Bound WCB Will Call Back WCB Wisconsin Certification Board WCB Western Commerce Bank (New Mexico) ) and full qualification, upstream and downstream manufacturing process development, and final product fill. ARIUS RESEARCH INC. is a biopharmaceutical company engaged in the discovery, development and delivery of drugs for individualized therapy. Individualized therapy is an innovative model of disease management focused on making the treatment fit each patient. Arius currently targets cancer and is designing monoclonal antibodies to enable oncologists to treat specific tumors for individual cancer patients. Initial indications include lung cancer, breast cancer and melanoma. Future research and development will include other solid tumors. Shares of Arius Research Inc. are traded on the CDNX under the symbol "YAR". CDNX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion